PRiME (Precision Medicine)
U of T-anchored hospital network among leading life sciences research hubs, report finds
The University of Toronto and its partner hospitals are propelling the Toronto region as a leading global hub for life sciences research – but its success is at risk from underinvestment. That’s among the findings of a new report that examines the strengths and challenges within the Toronto Academic Health Science Network (TAHSN) – which comprises U of T […]
Molly Shoichet named director of U of T's precision medicine initiative
Molly Shoichet has been named scientific director of PRiME Next-Generation Precision Medicine – an institutional strategic initiative that tackles unmet needs in drug discovery, diagnostics and disease biology. “It is such an exciting time in precision medicine,” says Shoichet, a University Professor in the Faculty of Applied Science & Engineering with a cross appointment to the Leslie Dan Faculty of Pharmacy who is […]
Canada’s opportunity in the future of genomics
One of U of T’s strengths lie in human genomics, which is supported by top-ranked faculty and researchers, anchored by a strong network of affiliated hospitals and medical research centers. Together, this network continues to advance frontiers of knowledge in critical areas of genomics including genetic susceptibility to disease, personalized medicine, machine learning for biomedical data, and more. Innovation hubs like the Emerging and Pandemic Infections Consortium (EPIC), Precision Medicine Initiative (PRiME), Medicine by Design, and the Structural Genomics Consortium are part of a network of high-impact interdisciplinary research centres that leverage areas of focus such as infectious disease, regenerative medicine, cell therapy, drug discovery, open science and more.
Researchers shrink brain tumours with gold nanoparticles, develop ‘mini brains’ to study psychiatric disorders
U of T researchers are inching closer to realizing a life-saving brain cancer treatment by using gold nanoparticles to make radiation therapy more effective and less toxic for patients. In their battle against glioblastoma multiforme (GBM), a rare, fast-growing cancer that begins in the brain, the multidisciplinary team has discovered that the nanoparticles can keep radiation tightly focused on the tumour, shrinking its size and preventing damage elsewhere in the body.
U OF T’S NEW PRECISION MEDICINE PROGRAM OFFERS TRAINING IN CROSS-DISCIPLINARY SCIENCE
JUNE 10, 2021 4:05PM A new graduate education program at the University of Toronto will provide PhD students with advanced education in interdisciplinary biomedical research. The Collaborative Specialization in Next-Generation Precision Medicine opened for enrolment this week and will offer courses this fall at the Leslie Dan Faculty of Pharmacy, the Temerty Faculty of Medicine, the Faculty of Arts & Science and […]
PRiME announces a Pan-Canadian Biomedical Innovation Showcase featuring research and industry leaders
2020 was an unprecedented year – a global pandemic stopped the world in its tracks. In 2021, we begin our recovery as an economy and a society as a worldwide vaccination effort is rolled out. The importance of biomedical innovation and the biotech sector has never been more evident: the vaccine needed to reopen our […]
PRiME researchers partner with TIAP and Amgen Inc. for biomanufacturing-focused project
December 8, 2020 PRiME researchers partner with TIAP and Amgen Inc. for biomanufacturing-focused project PRiME Director, Dr. Shana Kelley, together with Drs. Jason Moffat and Stephane Angers, has secured investment from the TIAP-Amgen partnership program to test a high-throughput cell-screening device that can enable the engineering of cells with superior antibody bioproduction capabilities. This collaboration […]
Start-ups founded by PRiME members attract major pharmaceutical partners and acquirers
Article from https://www.prime.utoronto.ca/news Start-up companies co-founded by PRiME faculty members, Sachdev Sidhu and Jason Moffat, have garnered the attention of major pharmaceutical partners, with several acquisitions transpiring over the last month. Earlier this week, Gilead Sciences purchased a stake in Pionyr Immunotherapeutics for $275M to access its Myeloid TuningTM approach to cancer immunotherapies. The technology, […]
PRiME announces a COVID-19 Task Force on Advanced Diagnostics and New Therapeutics
Article from https://www.prime.utoronto.ca/news As the global community responds to the COVID-19 pandemic, PRiME is convening its leading researchers to form a COVID-19 Task Force on Advanced Diagnostics and New Therapeutics to develop an arsenal of breakthroughs to fight COVID-19 and future pandemics. UofT researchers who are leading experts in disease biology, medicinal chemistry, device engineering, […]
Medicine by Design to accelerate regenerative medicine discovery and translation with new $20-million investment
Article from https://mbd.utoronto.ca/news/team-project-awards-cycle-2/ By AnnBy Ann Perry and Jovana Drinjakovic University Professor Shana Kelley (left) at the Leslie Dan Faculty of Pharmacy, Dr. Michael Laflamme (centre), a senior scientist at the McEwen Stem Cell Institute at University Health Network, and Freda Miller, a senior scientist at The Hospital for Sick Children, are leading three of […]